NCT00258700View on ClinicalTrials.gov

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Haemophilus Influenzae Type bNeisseria Meningitidis
Interventions
BIOLOGICAL

Haemophilus influenzae type b- and meningococcal (vaccine)

Trial Locations (10)

85-021

GSK Investigational Site, Bydgoszcz

80-394

GSK Investigational Site, Gdansk

25-711

GSK Investigational Site, Kielce

31-202

GSK Investigational Site, Krakow

91-347

GSK Investigational Site, Lodz

61-709

GSK Investigational Site, Poznan

41-103

GSK Investigational Site, Siemianowice Śląskie

55-100

GSK Investigational Site, Trzebnica

21-010

GSK Investigational Site, Łęczna

OX3 7LJ

GSK Investigational Site, Oxford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00258700 - Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine | Biotech Hunter | Biotech Hunter